Drug Profile
3DP 3534
Alternative Names: GW 395058; PEG-TPOLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer 3-Dimensional Pharmaceuticals
- Class Peptides
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Thrombocytopenia in United Kingdom (unspecified route)
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
- 06 Mar 2002 3-Dimensional Pharmaceuticals have announced a collaboration agreement with Inhale Therapeutic Systems